The anticancer agent prodigiosin induces p21WAF1/CIP1 expression via transforming growth factor-beta receptor pathway

Biochemical Pharmacology

Volumn 74, Issue 9, 2007, Pages 1340-1349

  Soto Cerrato, Vanessa ^a   Viñals, Francesc ^b,c   Lambert, James R ^d   Pérez Tomás, Ricardo ^a  

^a Cancer Cell Biology Research Group   (Spain)

^b BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

^d UNIVERSITY OF COLORADO   (United States)

Author keywords

Breast cancer; Cell cycle arrest; NAG 1; p21; Prodigiosin; TGF

Indexed keywords

4 [4 (1,3 BENZODIOXOL 5 YL) 5 (2 PYRIDINYL) 1H IMIDAZOL 2 YL]BENZAMIDE; ANTINEOPLASTIC AGENT; BETA ACTIN; CYCLIN DEPENDENT KINASE INHIBITOR 1; MESSENGER RNA; NONSTEROID ANTIINFLAMMATORY AGENT; PRODIGIOSIN; PROTEIN NAG 1; PROTEIN P53; THYMIDINE; TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; UNCLASSIFIED DRUG; VINCULIN;

APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE REGULATION; CELL STRAIN MCF 7; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; REAL TIME POLYMERASE CHAIN REACTION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZAMIDES; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DIOXOLES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; PRODIGIOSIN; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA; TUMOR SUPPRESSOR PROTEIN P53;

EID: 34548838585     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2007.07.016     Document Type: Article

References (50)

1. Williamson N.R., Fineran P.C., Leeper F.J., and Salmond G.P.C. The biosynthesis and regulation of bacterial prodiginines. Nat Rev Microbiol 4 12 (2006) 887-899
2. Han S.B., Kim H.M., Kim Y.H., Lee C.W., Jang E.S., Son K.H., et al. T-cell specific immunosuppression by prodigiosin isolated from Serratia marcescens. Int J Immunopharmacol 20 1-3 (1998) 1-13
3. Perez-Tomas R., Montaner B., Llagostera E., and Soto-Cerrato V. The prodigiosins, proapoptotic drugs with anticancer properties. Biochem Pharmacol 66 8 (2003) 1447-1452
4. Zang J., Shen Y., Liu J., and Wei D. Antimetastatic effect of prodigiosin through inhibition of tumor invasion. Biochem Pharmacol 69 3 (2005) 407-414
5. Montaner B., Navarro S., Pique M., Vilaseca M., Martinell M., Giralt E., et al. Prodigiosin from the supernatant of Serratia marcescens induces apoptosis in haematopoietic cancer cell lines. Br J Pharmacol 131 (2000) 585-593
6. Campas C., Dalmau M., Montaner B., Barragan M., Bellosillo B., Colomer D., et al. Prodigiosin induces apoptosis of B and T cells from B-cell chronic lymphocytic leukemia. Leukemia 17 4 (2003) 746-750
7. Diaz-Ruiz C., Montaner B., and Perez-Tomas R. Prodigiosin induces cell death and morphological changes indicative of apoptosis in gastric cancer cell line HGT-1. Histol Histopathol 16 2 (2001) 415-421
8. Montaner B., and Perez-Tomas R. Prodigiosin-induced apoptosis in human colon cancer cells. Life Sci 68 17 (2001) 2025-2036
9. Soto-Cerrato V., Llagostera E., Montaner B., and Perez-Tomas R. Mitochondria-mediated apoptosis operating irrespective of multidrug resistance in breast cancer cells by the anticancer agent prodigiosin. Biochem Pharmacol 68 7 (2004) 1345-1352
10. Llagostera E., Soto-Cerrato V., Joshi R., Montaner B., Gimenez-Bonafe P., and Perez-Tomas R. High cytotoxic sensitivity of the human small cell lung doxorubicin-resistant carcinoma (GLC4/ADR) cell line to prodigiosin through apoptosis activation. Anticancer Drugs 16 4 (2005) 393-399
11. - symporter) inhibit the acidification of lysosomes and induce cell cycle blockage in colon cancer cells. Life Sci 78 2 (2005) 121-127
12. Perez-Tomas R., and Montaner B. Effects of the proapoptotic drug prodigiosin on cell cycle-related proteins in Jurkat T cells. Histol Histopathol 18 2 (2003) 379-385
13. Melvin M.S., Wooton K.E., Rich C.C., Saluta G.R., Kucera G.L., Lindquist N., et al. Copper-nuclease efficiency correlates with cytotoxicity for the 4-methoxypyrrolic natural products. J Inorg Biochem 87 3 (2001) 129-135
14. Montaner B., Castillo-Avila W., Martinell M., Ollinger R., Aymami J., Giralt E., et al. DNA interaction and dual topoisomerase I and II inhibition properties of the anti-tumor drug prodigiosin. Toxicol Sci 85 2 (2005) 870-879
15. Soto-Cerrato V., Viñals F., Lambert J.R., Kelly J.A., and Pérez-Tomás R. Prodigiosin induces the proapoptotic gene NAG-1 via glycogen synthase kinase-3β activity in human breast cancer cells. Mol Cancer Ther 6 1 (2007) 362-369
16. Francisco R., Perez-Tomas R., Gimenez-Bonafe P., Soto-Cerrato V., Gimenez-Xavier P., and Ambrosio S. Mechanisms of prodigiosin cytotoxicity in human neuroblastoma cell lines. Eur J Pharmacol 572 (2007) 111-119
17. Massague J. TGF-beta signal transduction. Annu Rev Biochem 67 (1998) 753-791
18. Massague J., Blain S.W., and Lo R.S. TGF-β signalling in growth control, cancer, and heritable disorders. Cell 103 (2000) 295-309
19. Shi Y., and Massague J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 113 6 (2003) 685-700
20. Derynck R., and Zhang Y.E. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 425 6958 (2003) 577-584
21. Kang Y., Chen C.R., and Massague J. A self-enabling TGF-beta response coupled to stress signaling: Smad engages stress response factor ATF3 for Id1 repression in epithelial cells. Mol Cell 11 4 (2003) 915-926
22. Gartel A.L., and Serfas M.S. Tyner AL. p21-negative regulator of the cell cycle. Proc Soc Exp Biol Med 213 (1996) 138-149
23. El-Deiry W.S., Harper J.W., O'Connor P.M., Velculescu V.E., Canman C.E., Jackman J., et al. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 54 5 (1994) 1169-1174
24. Gartel A.L., and Tyner A.L. Transcriptional regulation of the p21 (WAF1/CIP1) gene. Exp Cell Res 246 (1999) 280-289
25. Tan M., Wang Y., Guan K., and Sun Y. PTGF-β, a type β transforming growth factor (TGF- β) superfamily member, is a p53 target gene that inhibits tumor cell growth via TGF- β signalling pathway. Proc Natl Acad Sci USA 97 1 (2000) 109-114
26. Liu T., Bauskin A.R., Zaunders J., Brown D.A., Pankhurst S., Russell P.J., et al. Macrophage inhibitory cytokine 1 reduces cell adhesion and induces apoptosis in prostate cancer cells. Cancer Res 63 16 (2003) 5034-5040
27. Li P.X., Wong J., Ayed A., Ngo D., Brade A.M., Arrowsmith C., et al. Placental transforming growth factor- β is a downstream mediator of the growth arrest and apoptotic response of tumor cells to DNA damage and p53 overexpression. J Biol Chem 275 26 (2000) 20127-20135
28. Baek S.J., Kim K.S., Nixon J.B., Wilson L.C., and Eling T.E. Cyclooxygenase inhibitors regulate the expression of a TGF-β superfamily member that has proapoptotic and antitumorigenic activities. Mol Pharmacol 59 4 (2001) 901-908
29. Newman D., Sakaue M., Koo J.S., Kim K.S., Baek S.J., Eling T., et al. Differential regulation of nonsteroidal anti-inflammatory drug-activated gene in normal human tracheobronchial epithelial and lung carcinoma cells by retinoids. Mol Pharmacol 63 3 (2003) 557-564
30. Wilson L.C., Baek S.J., Call A., and Eling T.E. Nonsteroidal anti-inflammatory drug-activated gene (NAG-1) is induced by genistein through the expression of p53 in colorectal cancer cells. Int J Cancer 105 6 (2003) 747-753
31. Baek S.J., Wilson L.C., and Eling T.E. Resveratrol enhances the expression of non-steroidal anti-inflammatory drug-activated gene (NAG-1) by increasing the expression of p53. Carcinogenesis 23 3 (2002) 425-434
32. Lambert J.R., Kelly J.A., Shim M., Huffer W.E., Nordeen S.K., Baek S.J., et al. Prostate derived factor in human prostate cancer cells: gene induction by vitamin D via a p53-dependent mechanism and inhibition of prostate cancer cell growth. J Cell Physiol 208 3 (2006) 566-574
33. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65 (1983) 55-63
34. Datto M.B., Li Y., Panus J.F., Howe D.J., Xiong Y., and Wang X.F. Transforming growth factor beta induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. Proc Natl Acad Sci USA 92 12 (1995) 5545-5549
35. Inman G.J., Nicolas F.J., Callahan J.F., Harling J.D., Gaster L.M., Reith A.D., et al. SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol Pharmacol 62 1 (2002) 65-74
36. Danforth Jr. D.N. All trans-retinoic acid acts synergistically with hydroxytamoxifen and transforming-growth factor beta to stimulate apoptosis in MCF-7 breast cancer cells. J Endocrinol 183 2 (2004) 395-404
37. Jang T.J., Kang H.J., Kim J.R., and Yang C.H. Non-steroidal anti-inflammatory drug activated gene (NAG-1) expression is closely related to death receptor-4 and -5 induction, which may explain sulindac sulfide induced gastric cancer cell apoptosis. Carcinogenesis 25 10 (2004) 1853-1858
38. Niculescu III A.B., Chen X., Smeets M., Hengst L., Prives C., and Reed S.I. Effects of p21(Cip1/Waf1) at both the G1/S and the G2/M cell cycle transitions: pRb is a critical determinant in blocking DNA replication and in preventing endoreduplication. Mol Cell Biol 18 1 (1998) 629-643
39. el-Deiry W.S., Tokino T., Velculescu V.E., Levy D.B., Parsons R., and Trent J.M. WAF1, a potential mediator of p53 tumor suppression. Cell 75 4 (1993) 817-825
40. Royds J.A., and Iacopetta B. p53 and disease: when the guardian angel fails. Cell Death Differ 13 6 (2006) 1017-1026
41. Pardali K., Kurisaki A., Moren A., ten Dijke P., Kardassis D., and Moustakas A. Role of Smad proteins and transcription factor Sp1 in p21 (Waf1/Cip1) regulation by transforming growth factor-beta. J Biol Chem 275 38 (2000) 29244-29256
42. Reiss M., and Barcellos-Hoff M.H. Transforming growth factor-beta in breast cancer: a working hypothesis. Breast Cancer Res Treat 45 1 (1997) 81-95
43. Derynck R., Akhurst R.J., and Balmain A. TGF-beta signaling in tumor suppression and cancer progression. Nat Genet 29 2 (2001) 117-129
44. Kang Y. Pro-metastasis function of TGFbeta mediated by the Smad pathway. J Cell Biochem 98 6 (2006) 1380-1390
45. Nazarova N., Qiao S., Golovko O., Lou Y.R., and Tuohimaa P. Calcitriol-induced prostate-derived factor: autocrine control of prostate cancer cell growth. Int J Cancer 112 6 (2004) 951-958
46. Montaner B., and Perez-Tomas R. The cytotoxic prodigiosin induces phosphorylation of p38-MAPK but not of SAPK/JNK. Toxicol Lett 129 1-2 (2002) 93-98
47. Tibbles L.A., and Woodgett J.R. The stress-activated protein kinase pathways. Cell Mol Life Sci 55 10 (1999) 1230-1254
48. Moon S.K., Choi Y.H., Kim C.H., and Choi W.S. p38MAPK mediates benzyl isothiocyanate-induced p21WAF1 expression in vascular smooth muscle cells via the regulation of Sp1. Biochem Biophys Res Commun 350 3 (2006) 662-668
49. Kim J.S., Baek S.J., Sali T., and Eling T.E. The conventional nonsteroidal anti-inflammatory drug sulindac sulphide arrests ovarian cancer cell growth via the expression of NAG-1/MIC-1/GDF-15. Mol Cancer Ther 4 3 (2005) 487-493
50. Seoane J., Le H.V., Shen L., Anderson S.A., and Massague J. Integration of Smad and forkhead pathways in the control of neuroepithelial and glioblastoma cell proliferation. Cell 117 2 (2004) 211-223